Treatment for Mild Chronic Hypertension during Pregnancy

dc.contributor.authorTita, Alan T.
dc.contributor.authorSzychowski, Jeff M.
dc.contributor.authorBoggess, Kim
dc.contributor.authorDugoff, Lorraine
dc.contributor.authorSibai, Baha
dc.contributor.authorLawrence, Kirsten
dc.contributor.authorHughes, Brenna L.
dc.contributor.authorBell, Joseph
dc.contributor.authorAagaard, Kjersti
dc.contributor.authorEdwards, Rodney K.
dc.contributor.authorGibson, Kelly
dc.contributor.authorHaas, David M.
dc.contributor.authorPlante, Lauren
dc.contributor.authorMetz, Torri
dc.contributor.authorCasey, Brian
dc.contributor.authorEsplin, Sean
dc.contributor.authorLongo, Sherri
dc.contributor.authorHoffman, Matthew
dc.contributor.authorSaade, George R.
dc.contributor.authorHoppe, Kara K.
dc.contributor.authorForoutan, Janelle
dc.contributor.authorTuuli, Methodius
dc.contributor.authorOwens, Michelle Y.
dc.contributor.authorSimhan, Hyagriv N.
dc.contributor.authorFrey, Heather
dc.contributor.authorRosen, Todd
dc.contributor.authorPalatnik, Anna
dc.contributor.authorBaker, Susan
dc.contributor.authorAugust, Phyllis
dc.contributor.authorReddy, Uma M.
dc.contributor.authorKinzler, Wendy
dc.contributor.authorSu, Emily
dc.contributor.authorKrishna, Iris
dc.contributor.authorNguyen, Nicki
dc.contributor.authorNorton, Mary E.
dc.contributor.authorSkupski, Daniel
dc.contributor.authorEl-Sayed, Yasser Y.
dc.contributor.authorOgunyemi, Dotum
dc.contributor.authorGalis, Zorina S.
dc.contributor.authorHarper, Lorie
dc.contributor.authorAmbalavanan, Namasivayam
dc.contributor.authorGeller, Nancy L.
dc.contributor.authorOparil, Suzanne
dc.contributor.authorCutter, Gary R.
dc.contributor.authorAndrews, William W.
dc.contributor.authorChronic Hypertension and Pregnancy (CHAP) Trial Consortium
dc.contributor.departmentObstetrics and Gynecology, School of Medicine
dc.date.accessioned2024-05-06T15:41:26Z
dc.date.available2024-05-06T15:41:26Z
dc.date.issued2022
dc.description.abstractBackground: The benefits and safety of the treatment of mild chronic hypertension (blood pressure, <160/100 mm Hg) during pregnancy are uncertain. Data are needed on whether a strategy of targeting a blood pressure of less than 140/90 mm Hg reduces the incidence of adverse pregnancy outcomes without compromising fetal growth. Methods: In this open-label, multicenter, randomized trial, we assigned pregnant women with mild chronic hypertension and singleton fetuses at a gestational age of less than 23 weeks to receive antihypertensive medications recommended for use in pregnancy (active-treatment group) or to receive no such treatment unless severe hypertension (systolic pressure, ≥160 mm Hg; or diastolic pressure, ≥105 mm Hg) developed (control group). The primary outcome was a composite of preeclampsia with severe features, medically indicated preterm birth at less than 35 weeks' gestation, placental abruption, or fetal or neonatal death. The safety outcome was small-for-gestational-age birth weight below the 10th percentile for gestational age. Secondary outcomes included composites of serious neonatal or maternal complications, preeclampsia, and preterm birth. Results: A total of 2408 women were enrolled in the trial. The incidence of a primary-outcome event was lower in the active-treatment group than in the control group (30.2% vs. 37.0%), for an adjusted risk ratio of 0.82 (95% confidence interval [CI], 0.74 to 0.92; P<0.001). The percentage of small-for-gestational-age birth weights below the 10th percentile was 11.2% in the active-treatment group and 10.4% in the control group (adjusted risk ratio, 1.04; 95% CI, 0.82 to 1.31; P = 0.76). The incidence of serious maternal complications was 2.1% and 2.8%, respectively (risk ratio, 0.75; 95% CI, 0.45 to 1.26), and the incidence of severe neonatal complications was 2.0% and 2.6% (risk ratio, 0.77; 95% CI, 0.45 to 1.30). The incidence of any preeclampsia in the two groups was 24.4% and 31.1%, respectively (risk ratio, 0.79; 95% CI, 0.69 to 0.89), and the incidence of preterm birth was 27.5% and 31.4% (risk ratio, 0.87; 95% CI, 0.77 to 0.99). Conclusions: In pregnant women with mild chronic hypertension, a strategy of targeting a blood pressure of less than 140/90 mm Hg was associated with better pregnancy outcomes than a strategy of reserving treatment only for severe hypertension, with no increase in the risk of small-for-gestational-age birth weight.
dc.eprint.versionAuthor's manuscript
dc.identifier.citationTita AT, Szychowski JM, Boggess K, et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med. 2022;386(19):1781-1792. doi:10.1056/NEJMoa2201295
dc.identifier.urihttps://hdl.handle.net/1805/40500
dc.language.isoen_US
dc.publisherMassachusetts Medical Society
dc.relation.isversionof10.1056/NEJMoa2201295
dc.relation.journalThe New England Journal of Medicine
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectAbruptio placentae
dc.subjectFetal growth retardation
dc.subjectHypertension
dc.subjectPre-eclampsia
dc.subjectPremature birth
dc.titleTreatment for Mild Chronic Hypertension during Pregnancy
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Tita2022Treatment-AAM.pdf
Size:
568.7 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: